Phaseline

Companies › SciRhom

SciRhom: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Immunology; next expected readout Feb 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SR-878
iRhom2 (RHBDF2) inhibitor
RHBDF2Phase 1Rheumatoid ArthritisFeb 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07433335SR-878Phase 1Rheumatoid ArthritisImmunologyFeb 2028

Targets

RHBDF2 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.